Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Bruce Sullenger
Univ of North Carolina Chapel Hill, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Tobira Therapeutics (formerly Regado Biosciences, Inc.)
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Sullenger has Tobira equity and licensed IP and will be the PI of this Duke subcontract. He will be responsible for the overall administration and direction of the project which proposes to develop a novel approach to generate animal models of human disease. He will review data generated by the investigators and work closely with colleagues from the University of North Carolina on the biochemical studies as well as aid in the design and interpretation of animal experiments. Dr. Sullenger is listed as an inventor on intellectual property used in this proposal (aptamer for coagulation factors) which was originally licensed to Regado Biosciences but is now owned by Tobira. This research is independent of Tobira Therapeutics.
Neutralizing Antibody & AAV FIX Gene Therapy
RELEVANCE (See instructions): Program Project Grant objective is to engineer, test, and validate next generation AAV vectors in novel animal models of bleeding disorders with pre-existing NAb in hope of extending the clinical success seen with scAAV FIX.
Filed on June 05, 2015.
Tell us what you know about Bruce Sullenger's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Bruce Sullenger”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Bruce Sullenger | Duke University | Conflict of Interest | Tobira Therapeutics | Value cannot be readily determined |
| Bruce Sullenger | Univ of North Carolina Chapel Hill | Conflict of Interest | Tobira Therapeutics (formerly Regado Biosciences, Inc.) | Value cannot be readily determined |
| Bruce Sullenger | Duke University | Conflict of Interest | Tobira Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.